Biology and treatment of Richter syndrome

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Molecular pathogenesis of splenic and nodal marginal zone lymphoma

Copyright © 2014 American Medical Association. All rights reserved.

Pathway analysis of primary central nervous system lymphoma

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with.

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

by Timothy P. Hughes, and David M. Ross

Next-generation leukemia immunotherapy

Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt-like” lymphomas from naive B cells by Delin Zhu, Chen Feng Qi,

by David W. Bahler, John A. Miklos, and Steven H. Swerdlow

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Thomas S. Uldrick, and Richard F. Little

Rituximab-induced tumor cell agglutination

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

Mechanisms of HIV-associated lymphocyte apoptosis

SOX11 holds mantle cell lymphoma’s key to home

Fusion genes in cord blood

Genetic sequence analysis of inherited bleeding diseases

Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK

AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation by Antonino Carbone, Annunziata Gloghini, Vincenzo Canzonieri, Umberto.

by Lewis Hsu, Bhalchandra Diwan, Jerrold M. Ward, and Constance T

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia by Rossana Maffei, Silvia Martinelli,

Significance of circulating T-cell clones in Sézary syndrome

Blood Volume 92(10): November 15, 1998

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas by Antonino Carbone, Annunziata Gloghini,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros

Anergy: the CLL cell limbo

HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8–positive plasmablastic lymphoma by Nicolas Dupin, Tim L.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Caught in transformation

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation by Wenbin Xiao, Mariko Yabe, Michael.

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults Xiao-Ping.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Altered pathways in prostate cancer.

K-Means clustering of protein and mRNA expression patterns after PPAR agonists treatments. k-Means clustering of protein and mRNA expression patterns after.

Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.

Bindiya Patel et al. BTS 2018;j.jacbts

by Geling Li, Emily Waite, and Julie Wolfson

Expression of σ in SCCs Expression of σ in SCCs. Shown is a magnified section of a representative 2D PAGE gel run with a lysate from an SCC.

Indirect immunofluorescence analysis of σ in bladder specimens, in normal urothelium (A, cyst 981; B, cyst 981; C, cyst 1004; and D, cyst 975), and.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Pathology slide of the meningeal tissue from a left temporal craniotomy shows inflammatory cells with lymphoplasmacytic infiltration, foamy histiocytes,

PD-L1 and tumor-associated macrophages in de novo DLBCL

by Matthew S. Painschab, Kate D

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

How I treat Burkitt lymphoma in adults

FCM and TCR γ gene rearrangement analysis in LGL leukemia.

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

How I treat early-relapsing follicular lymphoma

Initial treatment of CLL: integrating biology and functional status

Photomicrographs show metastatic lymph nodes from poorly (A) and highly (B) differentiated squamous cell carcinomas.A, Poorly differentiated cancer cells.

Lauren F. Damle, M. D. , Veronica Gomez-Lobo, M. D. , Amy R. Andrus, M

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Myeloid neoplasms with eosinophilia

A schematic approach to a patient with suspected RS

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

Biology and treatment of Richter syndrome by Davide Rossi, Valeria Spina, and Gianluca Gaidano Blood Volume 131(25):2761-2772 June 21, 2018 ©2018 by American Society of Hematology

Pathologic aspects of the lymph node in the CLL phase and in the DLBCL phase from a patient who experienced clonally related RS transformation. Pathologic aspects of the lymph node in the CLL phase and in the DLBCL phase from a patient who experienced clonally related RS transformation. Hematoxylin and eosin sections of CLL involved lymph node (A) and of DLBCL-type Richter transformation (B). The expression of CD20, CD5, CD23, and Ki67 detected by standard immunohistochemistry, the CLL-phase lymph node (C, E, G, I), and, for comparative purposes, in the DLBCL-type Richter transformation (D, F, H, J), are shown. Original magnification ×20 for all panels. Davide Rossi et al. Blood 2018;131:2761-2772 ©2018 by American Society of Hematology

Key molecular alterations of DLBCL-type RS Key molecular alterations of DLBCL-type RS. Genes and pathways that are molecularly deregulated are schematically represented. Key molecular alterations of DLBCL-type RS. Genes and pathways that are molecularly deregulated are schematically represented. The prevalence of molecular alterations is reported beside each gene or pathway. Davide Rossi et al. Blood 2018;131:2761-2772 ©2018 by American Society of Hematology

Algorithm for the management of DLBCL-type RS. Davide Rossi et al. Blood 2018;131:2761-2772 ©2018 by American Society of Hematology